Israeli multinational Teva Pharmaceuticals’ recent agreement with the Israeli State Attorney’s Office serves as an important reminder of the ongoing possibility of cumulative regulatory liabilities. After paying $519 million to settle charges with the U.S. government in late 2016, the company has now agreed to an additional fine of NIS 75 million (approximately $22 million). In this guest article, Shibolet & Co attorneys Chaim Gelfand and Daphna Otremski discuss the Teva affair and highlight some original local law enforcement measures employed by Israel in its efforts to combat corruption and bribery of public officials. See “Teva’s $519 Million FCPA Settlement Highlights Hazards of Local Production Requirements” (Jan. 18, 2017).